Publication details
Teriflunomid v léčbě relabující-remitující formy roztroušené sklerózy - imunomodulační mechanizmy
| Title in English | Teriflunomide in treating relapsing-remitting multiple sclerosis - immunomodulatory mechanisms |
|---|---|
| Authors | |
| Year of publication | 2016 |
| Type | Article in Periodical |
| Magazine / Source | Neurologie pro praxi |
| MU Faculty or unit | |
| Citation | |
| Field | Immunology |
| Keywords | multiple sclerosis; teriflunomide; immunomodulation; autoimmunity; PML; vaccination |
| Description | Multiple sclerosis (MS) is a chronic autoimmune disorder affecting the central nervous system through demyelination and neurodegeneration. Autoreactive lymphocytes penetrate the blood-brain barrier to attack the nervous system. Teriflunomide has recently been approved as a treatment of relapsing forms of MS. The main therapeutic effect is considered to be mediated via the inhibition of the de novo synthesis of pyrimidine leading to a reduction in proliferation of activated T and B cells without causing cell death. Vaccination with inactivated vaccines is possible during treatment with teriflunomide and leads to sufficient immune response. |